A research blog from the NCI Division of Cancer Prevention Subscribe The NCI Cancer Prevention Fellowship Program – Developing Multidisciplinary Scientists and Expanding the Cancer Prevention Workforce December 5, 2024 | By Jessica Faupel-Badger, Ph.D., M.P.H. & Alyssa Voss, M.P.H. The Cancer Prevention Fellowship Program (CPFP), NCI’s distinctive postdoctoral fellowship program that combines independent, mentored research with training in translational cancer prevention science, population health, leadership, and communication, is nearing its 40th anniversary. In light of this milestone, the CPFP, led by Acting Director, Jessica Faupel-Badger, Ph.D., M.P.H., took the opportunity to re-connect with program alumni across the globe and evaluate long-term outcomes of the program. A Deep Dive into Awareness and Perceptions of Potential Benefits and Harms of Multi-Cancer Detection Tests December 2, 2024 | By Goli Samimi, Ph.D., M.P.H. & Liz Freedman, M.S.W., M.P.H. Research is underway to try to address the many unanswered questions about cancer screening with multi-cancer detection (MCD) tests, a new type of blood test designed to detect multiple cancers. Targeting Prevention to Reduce the High Human Toll of Rare Cancers October 1, 2024 | By DCP Staff At the Rare Cancers Prevention and Interception workshop this year, cancer researchers from across the United States, Canada, and the United Kingdom and from across disciplines sought to address many of the issues that can hamper research progress for these diseases. Research Highlights: Looking Deep into Genetic Changes that Increase Colorectal Cancer Risk to Prevent or Detect Inherited Cancers September 10, 2024 | By DCP Staff Lynch syndrome, also known as hereditary non-polyposis colorectal cancer (HNPCC), is the most common inherited genetic change that increases the risk of several kinds of cancer including colorectal cancer. About 3% of all colorectal cancers in the United States occur in people with these inherited genetic changes; more than 1 million people in the U.S. have this syndrome. Defining Patient Tolerability to Cancer Treatments Helps Reduce Negative Outcomes May 23, 2024 | By DCP Staff For decades, cancer patients have participated in clinical trials of new therapies, and clinicians have assessed and recorded any adverse or toxic reactions to the treatments. Over the years, researchers have standardized the reporting of those side effects using Common Terminology Criteria for Adverse Events (CTCAE). Pagination Next page < Older Blog Posts
